Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 5/2016

01-10-2016

Prevention of Contrast-Induced Acute Kidney Injury: an Update

Authors: George Chalikias, Ioannis Drosos, Dimitrios N. Tziakas

Published in: Cardiovascular Drugs and Therapy | Issue 5/2016

Login to get access

Abstract

Contrast-induced acute kidney injury (CI-AKI) is a common complication of intravascular administration of contrast media used in coronary angiography, percutaneous coronary intervention and other diagnostic and interventional procedures. This review article aims at summarizing the published literature regarding the prevention of CI-AKI, by focusing on available high-quality meta-analyses addressing this matter. Apart from adequate hydration, a number of pharmacologic agents have been proposed as potential candidates to be included in the routine preparation, prior to the patient’s arrival in the cardiac catheterization laboratory. Among them, statins and N-acetylcysteine appear to be the most extensively studied ones. Throughout this article we present the available data on CI-AKI prevention and provide a critical clinical appraisal, as well as a summary of currently available guidelines.
Appendix
Available only for authorised users
Literature
1.
Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–6.CrossRefPubMed
2.
3.
Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39(7):1113–9.CrossRefPubMed
4.
James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: A systematic review and meta-analysis. Circ Cardiovasc Interv. 2013;6(1):37–43.CrossRefPubMed
5.
Wi J, Ko YG, Kim JS, Kim BK, Choi D, Ha JW, et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart. 2011;97(21):1753–7.CrossRefPubMed
6.
Oduncu V, Erkol A, Karabay CY, Sengul C, Tanalp AC, Fotbolcu H, et al. Relation of the severity of contrast induced nephropathy to SYNTAX score and long term prognosis in patients treated with primary percutaneous coronary intervention. Int J Cardiol. 2013;168(4):3480–5.CrossRefPubMed
7.
Chalikias G, Drosos I, Tziakas DN. Contrast-induced acute kidney injury: an update. Cardiovasc Drugs Ther. 2016.
8.
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter, Suppl. 2012;2(1):1-138.
9.
Jurado-Roman A, Hernandez-Hernandez F, Garcia-Tejada J, Granda-Nistal C, Molina J, Velazquez M, et al. Role of hydration in contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention. Am J Cardiol. 2015;115(9):1174–8.CrossRefPubMed
10.
Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162(3):329–36.CrossRefPubMed
11.
Lindinger MI, Franklin TW, Lands LC, Pedersen PK, Welsh DG, Heigenhauser GJ. NaHCO(3) and KHCO(3) ingestion rapidly increases renal electrolyte excretion in humans. J Appl Physiol (1985). 2000;88(2):540–550.
12.
Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291(19):2328–34.CrossRefPubMed
13.
Zhang B, Liang L, Chen W, Liang C, Zhang S. The efficacy of sodium bicarbonate in preventing contrast-induced nephropathy in patients with pre-existing renal insufficiency: a meta-analysis. BMJ Open. 2015;5(3):e006989.
14.
Hoste EA, De Waele JJ, Gevaert SA, Uchino S, Kellum JA. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant. 2010;25(3):747–58.CrossRefPubMed
15.
Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med. 2009;7:23.
16.
Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim TH, et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury - A systematic review and meta-analysis. Circ J. 2012;76(9):2255–65.CrossRefPubMed
17.
Kunadian V, Zaman A, Spyridopoulos I, Qiu W. Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials. Eur J Radiol. 2011;79(1):48–55.CrossRefPubMed
18.
Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53(4):617–27.CrossRefPubMed
19.
Gu G, Zhang Y, Lu R, Cui W. Additional furosemide treatment beyond saline hydration for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(1):387–94.PubMedPubMedCentral
20.
Duan N, Zhao J, Li Z, Dong P, Wang S, Zhao Y, et al. Furosemide with saline hydration for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: A meta-analysis of randomized controlled trials. Med Sci Monit. 2015;21:292–7.CrossRefPubMedPubMedCentral
21.
Yang B, Xu J, Xu F, Zou Z, Ye C, Mei C, et al. Intravascular administration of mannitol for acute kidney injury prevention: A systematic review and meta-analysis. PLoS One. 2014;9(1):e85029.CrossRefPubMedPubMedCentral
22.
Dorval JF, Dixon SR, Zelman RB, Davidson CJ, Rudko R, Resnic FS. Feasibility study of the RenalGuard balanced hydration system: a novel strategy for the prevention of contrast-induced nephropathy in high risk patients. Int J Cardiol. 2013;166(2):482–6.CrossRefPubMed
23.
Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124(11):1260–9.CrossRefPubMed
24.
Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012;5(1):90–7.CrossRefPubMed
25.
Briguori C, Visconti G, Donahue M, De Micco F, Focaccio A, Golia B, et al. RenalGuard system in high-risk patients for contrast-induced acute kidney injury. Am Heart J. 2016;173:67–76.CrossRefPubMed
26.
Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: The POSEIDON randomised controlled trial. Lancet. 2014;383(9931):1814–23.CrossRefPubMed
27.
Qian G, Fu Z, Guo J, Cao F, Chen Y. Prevention of Contrast-Induced Nephropathy by Central Venous Pressure-Guided Fluid Administration in Chronic Kidney Disease and Congestive Heart Failure Patients. JACC Cardiovasc Interv. 2016;9(1):89–96.CrossRefPubMed
28.
Maioli M, Toso A, Leoncini M, Musilli N, Bellandi F, Rosner MH, et al. Pre-procedural bioimpedance vectorial analysis of fluid status and prediction of contrast-induced acute kidney injury. J Am Coll Cardiol. 2014;63(14):1387–94.CrossRefPubMed
29.
30.
Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol. 2008;295(1):F53–9.CrossRefPubMedPubMedCentral
31.
Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004;62(4):273–8.CrossRefPubMed
32.
Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118(8):843–9.CrossRefPubMed
33.
Marenzi G, Cosentino N, Werba JP, Tedesco CC, Veglia F, AL. B. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol. 2015;183:47–53.CrossRefPubMed
34.
Giacoppo D, Capodanno D, Capranzano P, Aruta P, Tamburino C. Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. Am J Cardiol. 2014;114(4):541–8.CrossRefPubMed
35.
Ukaigwe A, Karmacharya P, Mahmood M, Pathak R, Aryal MR, Jalota L, et al. Meta-analysis on efficacy of statins for prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography. Am J Cardiol. 2014;114(9):1295–302.CrossRefPubMed
36.
Briasoulis A, Mallikethi-Reddy S, Sharma S, Briasouli AA, Afonso L. 3-Hydroxy-3-methylglutaryl-CoA reductase enzyme inhibitors for prevention of contrast-induced nephropathy: a meta-analysis of prospective randomized controlled studies. Am J Ther. 2015;22(6):e158–66.CrossRefPubMed
37.
Liu YH, Liu Y, Duan CY, Tan N, Chen JY, Zhou YL, et al. Statins for the Prevention of Contrast-Induced Nephropathy After Coronary Angiography/Percutaneous Interventions: A meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2015;20(2):181–92.CrossRefPubMed
38.
Lee JM, Park J, Jeon KH, Jung JH, Lee SE, Han JK, et al. Efficacy of short-term high-dose statin pretreatment in prevention of contrast-induced acute kidney injury: Updated study-level meta-analysis of 13 randomized controlled trials. PLoS One. 2014;9(11):e111397.CrossRefPubMedPubMedCentral
39.
Xie H, Ye Y, Shan G, Zhang S, Fang Q, Yang D, et al. Effect of statins in preventing contrast-induced nephropathy: An updated meta-analysis. Coron Artery Dis. 2014;25(7):565–74.CrossRefPubMed
40.
Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, Webb JG. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Pharmacotherapy. 2005;25(8):1095–103.CrossRefPubMed
41.
Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180–4.CrossRefPubMed
42.
Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, Sweny P, et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: A randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004;40(6):1136–41.CrossRefPubMed
43.
Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: Lack of effect. Am Heart J. 2004;148(3):422–9.CrossRefPubMed
44.
O'Sullivan S, Healy DA, Moloney MC, Grace PA, Walsh SR. The role of N--acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis. Angiology. 2013;64(8):576–82.CrossRefPubMed
45.
MY W, Hsiang HF, Wong CS, Yao MS, Li YW, Hsiang CY, et al. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: A meta-analysis of randomized controlled trials. Int Urol Nephrol. 2013;45(5):1309–18.CrossRef
46.
Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One. 2013;8(1):e55124.CrossRefPubMedPubMedCentral
47.
Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151(1):140–5.CrossRefPubMed
48.
Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med 2004;2:38.
49.
Jacobs C, Hutton B, Ng T, Shorr R. Clemons M. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. Oncologist. 2015;20(2):210–23.CrossRefPubMedPubMedCentral
50.
Arrigoni O, De Tullio MC. Ascorbic acid: Much more than just an antioxidant. Biochim Biophys Acta 2002;1569(1–3):1–9.
51.
Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110(18):2837–42.CrossRefPubMed
52.
Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol. 2013;62(23):2167–75.CrossRefPubMed
53.
Erley CM, Duda SH, Schlepckow S, Koehler J, Huppert PE, Strohmaier WL, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int. 1994;45(5):1425–31.CrossRefPubMed
54.
Dai B, Liu Y, Fu L, Li Y, Zhang J, Mei C. Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2012;60(3):360–70.CrossRefPubMed
55.
Akgullu C, Saruhan T, Eryilmaz U, Boyacioglu M, Onbasili OA, Meteoglu I, et al. The first histopathological evidence of trimetazidine for the prevention of contrast-induced nephropathy. Ren Fail. 2014;36(4):575–80.CrossRefPubMed
56.
Ozden A, Aybek Z, Saydam N, Calli N, Saydam O, Duzcan E, et al. Cytoprotective effect of trimetazidine on 75 min warm renal ischemia-reperfusion injury in rats. Eur Surg Res. 1998;30(4):227–34.CrossRefPubMed
57.
Nadkarni GN, Konstantinidis I, Patel A, Yacoub R, Kumbala D, Patel RA, et al. Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2015;20(6):539–46.CrossRefPubMed
58.
Peguero JG, Cornielle V, Gomez SI, Issa OM, Heimowitz TB, Santana O, et al. The use of nitrates in the prevention of contrast-induced nephropathy in patients hospitalized after undergoing percutaneous coronary intervention. J Cardiovasc Pharmacol Ther. 2014;19(3):310–4.CrossRefPubMed
59.
Nichols AJ, Ruffolo RR, Jr., Brooks DP. The pharmacology of fenoldopam. Am J Hypertens. 1990;3(6 Pt 2):116s–9s.
60.
Talati S, Kirtane AJ, Hassanin A, Mehran R, Leon MB, Moses JW, et al. Direct infusion of fenoldopam into the renal arteries to protect against contrast-induced nephropathy in patients at increased risk. Clin Exp Pharmacol Physiol. 2012;39(6):506–9.CrossRefPubMed
61.
Firouzi A, Maadani M, Kiani R, Shakerian F, Sanati HR, Zahedmehr A, et al. Intravenous magnesium sulfate: New method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention. Int Urol Nephrol. 2015;47(3):521–5.CrossRefPubMed
62.
Ahmad A, Mondello S, Di Paola R, Mazzon E, Esposito E, Catania MA, et al. Protective effect of apocynin, A NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. Eur J Pharmacol. 2012;674(2–3):397–406.CrossRefPubMed
63.
Aslanger E, Uslu B, Akdeniz C, Polat N, Cizgici Y, Oflaz H. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty. Coron Artery Dis. 2012;23(4):265–70.CrossRefPubMed
64.
Markota D, Markota I, Starcevic B, Tomic M, Prskalo Z, Brizic I. Prevention of contrast-induced nephropathy with Na/K citrate. Eur Heart J. 2013;34(30):2362–7.CrossRefPubMed
65.
Koch C, Chaudru S, Lederlin M, Jaquinandi V, Kaladji A, Mahe G. Remote ischemic preconditioning and contrast-induced nephropathy: a systematic review. Ann Vasc Surg. 2016.
66.
Menting TP, Sterenborg TB, de Waal Y, Donders R, Wever KE, Lemson MS, et al. Remote Ischemic Preconditioning To Reduce Contrast-Induced Nephropathy: A randomized controlled trial. Eur J Vasc Endovasc Surg. 2015;50(4):527–32.CrossRefPubMed
67.
Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E et al. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: Randomized pilot RenPro trial (renal protection trial). Circulation 2012;126(3):296–303.
68.
Sekiguchi H, Ajiro Y, Uchida Y, Ishida I, Otsuki H, Hattori H, et al. Oxygen pre-conditioning prevents contrast-induced nephropathy (OPtion CIN Study). J Am Coll Cardiol. 2013;62(2):162–3.CrossRefPubMed
69.
Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med 2012;125(1):66–78.e3.
70.
Duffy SJ, Ruygrok P, Juergens CP, Sievert H, Richards M, Blake J, et al. Removal of contrast media from the coronary sinus attenuates renal injury after coronary angiography and intervention. J Am Coll Cardiol. 2010;56(6):525–6.CrossRefPubMed
71.
Watson T, Burd JS, Ruygrok PN. Prevention of contrast induced nephropathy during coronary angiography with a coronary sinus contrast removal system sited from the femoral vein. Int J Cardiol. 2013;165(1):e9–10.CrossRefPubMed
72.
Minsinger KD, Kassis HM, Block CA, Sidhu M, Brown JR. Meta-analysis of the effect of automated contrast injection devices versus manual injection and contrast volume on risk of contrast-induced nephropathy. Am J Cardiol. 2014;113(1):49–53.CrossRefPubMed
73.
Kaye DM, Stub D, Mak V, Doan T, Duffy SJ. Reducing iodinated contrast volume by manipulating injection pressure during coronary angiography. Catheter Cardiovasc Interv. 2014;83(5):741–5.CrossRefPubMed
74.
Prasad A, Ortiz-Lopez C, Kaye DM, Byrne M, Nanayakkara S, Ahmed SH, et al. The use of the AVERT system to limit contrast volume administration during peripheral angiography and intervention. Catheter Cardiovasc Interv. 2015;86(7):1228–33.CrossRefPubMed
75.
76.
Malik A. Prevention of contrast-induced acute kidney injury. Br J Hosp Med (Lond). 2015;76(12):685–9.CrossRef
77.
Rim MY, Ro H, Kang WC, Kim AJ, Park H, Chang JH, et al. The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: A propensity-matched study. Am J Kidney Dis. 2012;60(4):576–82.CrossRefPubMed
78.
Bainey KR, Rahim S, Etherington K, Rokoss ML, Natarajan MK, Velianou JL, et al. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial. Am Heart J. 2015;170(1):110–6.CrossRefPubMed
79.
Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J. 2014;65(2):96–105.
80.
Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology. 2010;254(1):261–9.CrossRefPubMed
81.
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2012. 2011;79(3):453–95.CrossRef
82.
Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014. 2014;35(37):2541–619.
Metadata
Title
Prevention of Contrast-Induced Acute Kidney Injury: an Update
Authors
George Chalikias
Ioannis Drosos
Dimitrios N. Tziakas
Publication date
01-10-2016
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 5/2016
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-016-6683-0

Other articles of this Issue 5/2016

Cardiovascular Drugs and Therapy 5/2016 Go to the issue

REVIEW ARTICLE

New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications

ORIGINAL ARTICLE

Amiodarone Compared with Lidocaine for Out-Of-Hospital Cardiac Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a Nationwide Database Study

ORIGINAL ARTICLE

Reduction of Atherosclerotic Lesions by the Chemotherapeutic Agent Carmustine Associated to Lipid Nanoparticles

REVIEW ARTICLE

Insulin in Acute Coronary Syndrome: a Narrative Review with Contemporary Perspectives

ORIGINAL ARTICLE

Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data

ORIGINAL ARTICLE

Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits